Nyxoah Completes $50M Offering And Subsequent Sale Of Additional Shares, Raising $52.5M
Nyxoah Completes $50M Offering And Subsequent Sale Of Additional Shares, Raising $52.5M
Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.
Nyxoah打算利用擬議中的發行所得款項(i)用於在美國進行商業化前和商業化活動；(ii)繼續收集臨床數據並支持與OSA患者治療相關的醫生主導的臨床研究項目；(iii)進一步融資下一代Genio系統的研究和開發活動，並繼續建立一系列新技術和探索OSA監測和診斷領域的潛在合作機會；以及(iv)用於其他一般企業目的，包括但不限於營運資金、固定資產支出、投資、收購（如果公司決定追求任何），以及合作。
譯文內容由第三人軟體翻譯。